| Literature DB >> 15577101 |
Abstract
Magnesium ion blocks the ion channel of the NMDA receptor at a stable condition. The ion channel competes with the binding site of the noncompetitive antagonists phencyclidine (PCP) and MK-801, which prevent a brain impairment due to the ischemia and so on. The binding ability of these antagonists is strong, an exchange with the magnesium ion is not easy, then the side effect of the schizophrenia-like behavior is caused. Recently, memantine can be used as a therapeutic drug of the moderate-to-severe Alzheimer's disease. Memantine is the noncompetitive antagonist, too, then those development details and a difference from MK-801 were explained.Entities:
Mesh:
Substances:
Year: 2004 PMID: 15577101 DOI: CliCa040812541258
Source DB: PubMed Journal: Clin Calcium ISSN: 0917-5857